Autopsy series indicate that, while neocortical LB pathology is the principal substrate of dementia, one-third of PDD cases exhibit moderate–severe tau and half have moderate–severe Aβ, and higher tau/Aβ burdens track faster cognitive decline and mortality, suggesting that concurrent tau targeting could enhance disease modification in cognitively vulnerable PD populations [211]. The gene discussed is MAPT; the disease is dementia.